XBI - SPDR S&P Biotech ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
93.38
-0.61 (-0.65%)
As of 10:53AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close93.99
Open94.05
Bid0.00 x 900
Ask0.00 x 900
Day's Range93.20 - 94.24
52 Week Range74.44 - 101.55
Volume908,985
Avg. Volume4,341,058
Net Assets5.33B
NAV95.16
PE Ratio (TTM)N/A
Yield0.20%
YTD Return12.42%
Beta (3y)1.91
Expense Ratio (net)0.35%
Inception Date2006-01-31
Trade prices are not sourced from all markets
  • Final Trade: AXP, XBI & more
    CNBC Videoslast month

    Final Trade: AXP, XBI & more

    The "Fast Money" traders share their final trades of the day, including American Express, the XBI biotech ETF, Sabra Health Care REIT and Twitter.

  • Drug pricing debate could heat up in July
    CNBC Videos2 months ago

    Drug pricing debate could heat up in July

    CNBC's Meg Tirrell reports on drug prices and hikes that have already occurred this month. With Michael Yee, Jefferies.

  • Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth
    Market Realist11 days ago

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.

  • A Look at Ionis’s Revenue Streams in the Second Quarter
    Market Realist12 days ago

    A Look at Ionis’s Revenue Streams in the Second Quarter

    As discussed earlier, Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to revenues of $112 million during the second quarter of 2017. Ionis missed Wall Street analyst estimates for revenues and EPS in Q2 2018. Ionis reported commercial revenues of $57 million during Q2 2018, over 100% growth as compared to commercial revenues of $24 million during the second quarter of 2017.

  • What to Expect from Sarepta’s Second-Quarter Earnings
    Market Realist13 days ago

    What to Expect from Sarepta’s Second-Quarter Earnings

    Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company. Sarepta develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases.

  • Investopedia18 days ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • Biogen Stock Trending Higher on Strong Q2 2018 Results
    Market Realist27 days ago

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. The company’s sales and earnings came in ahead of Wall Street estimates. Biogen’s spinal muscular atrophy drug, Spinraza, registered sales of $423 million in Q2 2018, which almost doubled compared to the $203 million sales reported in Q2 2017.

  • MarketWatch27 days ago

    Biotech ETFs surge, supported by strong results from Biogen and Eli Lilly

    MARKET PULSE Exchange-traded funds tracking the biotechnology sector rallied on Tuesday, supported by stronger-than-expected quarterly results from a pair of major components. The iShares Nasdaq Biotechnology ETF (IBB) gained 1.

  • Investopedialast month

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • Barrons.comlast month

    Biotech Earnings: Second Quarter May Not Beat the Street

    First-quarter earnings season may have suffered from low expectations, but the second quarter is traditionally a stronger one for the biotech industry, and there's more optimism heading into individual company reports. Leerink's Geoffrey Porges disagrees with the bulls this time around, however.

  • What Investors Need to Know about Biotech ETFs
    Zackslast month

    What Investors Need to Know about Biotech ETFs

    Smaller biotech stocks are outperforming this year; learn more about biotech ETFs best positioned to benefit

  • MarketWatchlast month

    Biotech ETFs surge, lifted as Biogen sees best session in more than a decade

    MARKET PULSE Exchange-traded funds that track the biotechnology sector jumped on Friday, supported by a huge gain in industry bellwether Biogen, which climbed after a positive drug trial. The iShares Nasdaq Biotechnology ETF (IBB) jumped 2.

  • InvestorPlace2 months ago

    Best ETFs for 2018: The Powershares QQQ Trust Is Hooked Up

    This article is a part of InvestorPlace’s Best ETFs for 2018 contest. The readers’ choice for the contest is the PowerShares QQQ Trust ETF (NASDAQ:QQQ). Tech stocks have been on a heck of a ride this year.

  • Barrons.com2 months ago

    Five Biotech Stocks to Pick Up on the Cheap

    With second-quarter earnings coming up, Bernstein's Aaron (Ronny) Gal takes a look at what to expect from some biotech firms. The iShares Nasdaq Biotechnology ETF (IBB) is down 0.2% to $110.49, and the SPDR S&P Biotech ETF (XBI) is falling 0.3% to $95.98 tis morning.  Sign up to Review & Preview, a new daily email from Barron’s. Every evening we’ll review the news that moved markets during the day and look ahead to what it means for your portfolio in the morning.

  • Trending: Technology Sector Surges to Record Highs Despite Trade Jitters
    ETF Database2 months ago

    Trending: Technology Sector Surges to Record Highs Despite Trade Jitters

    Investors have bought into the technology sector with fervor as markets enjoyed a brief period of tranquility just before politicians resumed their belligerent rhetoric.

  • ETF Trends2 months ago

    Sarepta Therapeutics Helps Biotech ETFs Buck Market Trend

    Biotechnology sector-related exchange traded funds were among the few areas of the markets that shook off the tariffs-talk volatility and was still in the green Tuesday as Sarepta Therapeutics (SRPT) surged on positive preliminary results from its experimental treatment. The BioShares Biotechnology Products Fund (BBP) , which follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, and SPDR S&P Biotech ETF (XBI) , which takes an equal-weight approach to the biotech space, were among the better performing ETFs Tuesday, rising 2.2% and 1.3%, respectively. Meanwhile, the iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotech exchange traded fund by assets, was 1.3% higher Tuesday.

  • Biotech Funds Tacked On $76 Million This Week — Are They Recovering?
    Investor's Business Daily2 months ago

    Biotech Funds Tacked On $76 Million This Week — Are They Recovering?

    Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon the group hasn't seen in nine months.

  • Investopedia2 months ago

    Why Biotech Stocks May Reach New Highs

    Biotech stocks are nearing a big break out as measured by the SPDR S&P Biotech ETF ( XBI). The group is already having a strong start to 2018, quietly outpacing not only the S&P 500 but the most talked about sectors in the market, technology ( XLK) and consumer stocks ( XLY). The biotech ETF is sitting right below a significant resistance level at $97.90, the previous all-time high for the ETF, and should that price rise above technical resistance, it would mark a big breakout.

  • Biotech Sector Continue to Dazzle Despite Market Distress
    Market Realist2 months ago

    Biotech Sector Continue to Dazzle Despite Market Distress

    Biotech stocks—with their binary outcomes and potential FDA approvals or denials—should whip around, pending various outcomes. It doesn’t help that President Trump (seemingly at random) decides periodically that we all pay too much for drugs. For biotech stocks to work on the long side investors’ risk appetite would have to take off or a major approval could drive the stocks up.

  • CNBC3 months ago

    Cramer: Pharmaceutical stocks are underperforming 'like nothing I've ever seen'

    CNBC's Jim Cramer says that he is disappointed by the recent performance of pharmaceutical stocks, saying there should be far more deals in the health-care space. Cramer says despite pharma's underperformance, he likes biotech stocks, which have been making a bit of a comeback this year. CNBC's Jim Cramer said Monday that he is disappointed by the recent performance of pharmaceutical stocks, saying there should be far more deals in the health-care space.

  • Benzinga3 months ago

    Analysis: White House Takes Bully Pulpit Approach On Drug Pricing Reform, Congress Unlikely To Act

    President Donald Trump is keeping pharmaceutical execs, lobbyists and investors on their toes. “[The notice] is consistent with his administration's ‘bully pulpit’ strategy of cajoling the drug makers into industry-led changes to drug pricing,” Height analyst Andrea Harris said in a note.

  • Barrons.com3 months ago

    Will Big Data Lead to Big Biotech Returns?

    Big Data could improve results in the biopharmaceutical industry—if companies can improve their use and avoid pitfalls, writes Jefferies' Michael Yee in a report issued today. The proper implementation of new data and analytics tools could "accelerate the probability of success" in the drug industry and boost process efficiencies, driving billions in cost savings, according to Yee. In this way, using Big Data to "find better drugs at a lower cost" will put drug makers at an advantage by increasing return on investment. Companies that are using Big Data include Amgen (AMGN), Biogen (BIIB), Celgene (CELG), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Eli Lilly (LLY), Merck (MRK), Novartis (NVS), and Regeneron Pharmaceuticals (REGN).

  • Benzinga3 months ago

    'Right To Try' Law Signed By Trump Increases Patient Access To Experimental Drugs

    Under the new law, terminally ill patients who are ineligible for clinical trials and have exhausted all treatment options will now be allowed to test experimental therapies not yet approved by the FDA. In providing a workaround for the FDA’s long and arduous trial processes, the law accelerates the time it takes for patients to access a new formula and may make it easier for clinical-stage pharmaceuticals developing orphan drugs to test their products.

  • Biotech ETFs Are the Best Way to Play the Recovering Sector
    InvestorPlace3 months ago

    Biotech ETFs Are the Best Way to Play the Recovering Sector

    The summer of 2015 marked the end of the glory years in the biotechnology sector. The biotech valuation correction that lasted over two years may be coming to an end. Some well-known, large-cap names — such as AbbVie Inc (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) — are currently trading at forward P/E multiples in the 10+ range.

  • A Look at Incyte’s Valuation as of May 25
    Market Realist3 months ago

    A Look at Incyte’s Valuation as of May 25

    Incyte Corporation (INCY) is a biopharmaceutical company with headquarters in Wilmington, Delaware. Incyte’s business includes the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.